Drug assessment at a glance: A26-62[1]

Remibrutinib (chronic spontaneous urticaria)

3 November 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-62. The GBA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with chronic spontaneous urticaria with inadequate response to H1 antihistamines
Intervention	remibrutinib
Comparator	omalizumab in combination with second-generation H1 antihistamines
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: no advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No relevant study was identified.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Remibrutinib (chronische spontane Urtikaria); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 01.09.2026]. URL: https://doi.org/10.60584/A26-62.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Remibrutinib (chronische spontane Urtikaria) [online]. 2026 [Accessed: 01.09.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1359/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-62.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de